Skip to main content
OpenTrials
Completed

NCT Number: NCT03453372

MRgFUS in the Treatment of Osteoarthritic Knee Pain

A double-blind placebo-controlled randomized clinical trial to evaluate the efficacy of magnetic resonance-guided focused ultrasound surgery (MRgFUS) in the treatment of pain caused by knee osteoarthritis (OA)

Completed

Looking for future studies?

Notify Me

Key information

Age range

50 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Istituto Ortopedico Rizzoli

Bologna, BO, 40136, Italy

About this study

Osteoarthritis (OA) is a common, disabling, and costly disease, and the knee is one of the most affected joints. The predominant symptom is pain. Effective and lasting non-invasive treatment approaches are missing. MR-guided focused ultrasound surgery (MRgFUS) is a new minimally invasive technique which may represent a valid solution providing several advantages. The primary aim of this work will be to assess the efficacy of MRgFUS in the treatment of pain caused by knee OA in 80 patients candidate for arthroplasty in a prospective, randomized, double-blinded, placebo-controlled clinical trial. Different parameters related to pain, quality of life, function, and imaging will be collected and analyzed in a 12-month follow-up. The secondary aims will be focused on a) the evaluation of the effects on the joint organ and changes of biological features in response to MRgFUS, and b) the impact of selective ablation of nociceptors on OA pain, based on the analysis of resected joint tissues.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male and female aged 50-80 years
  • Activity-related joint pain
  • Patients who have not responded to previous treatments and patients candidate for surgery
  • Kellgren-Lawrence score 2-4 on X-rays
  • Patients able to give their informed consent

Exclusion criteria

  • Prior surgery in the past 12 months or previous local treatment in the past 3 months
  • Changes in medications used during the previous 2 months
  • Corticosteroid use for more than 3 months within the preceding year
  • Rheumatologic and neurological disorders
  • Fibromyalgia
  • Trauma, fracture or osteomyelitis of the investigated joints within the preceding year
  • Pregnancy
  • Patients with large scars potentially included in the ultrasound beam path
  • General contraindications to MRI and/or to anaesthesiological procedures
  • Presence of internal hardware or device potentially affecting MR thermometry
  • Patients involved in other clinical studies

Treatment and study plan

MRgFUS Treatment

Device

Treatment of pain caused by knee osteoarthritis with high-intensity focused ultrasound

Placebo

Other

Procedures in the placebo group will be identical to procedures in the active group, except no sonications (ultrasound emission) will be used.

Primary outcomes

  1. Efficacy of MRgFUS in the treatment of pain caused by knee OA

    Time frame: Baseline (Day 1), 24 hours post MRgFUS, Week 1, 2, 3, Month 1, 3, 6,12

    The efficacy of MRgFUS will be demonstrated if the treatment group has a mean reduction of Visual Analog Pain Scale (VAS) of at least 1.5 points greater than the control group.

Secondary outcomes

  1. Effects of MRgFUS on the joint organ: inflammation

    Time frame: Baseline (Day 1), 24 hours post MRgFUS, Month 1, 3, 6,12

    Enzyme linked immuno assays kits will be used to test inflammatory markers in serum. The reference standard values of the standardized markers will be considered for the evaluations.

  2. Effects of MRgFUS on the joint organ: bone turnover

    Time frame: Baseline (Day 1), 24 hours post MRgFUS, Month 1, 3, 6,12

    Enzyme linked immuno assays kits will be used to test bone turnover markers in serum. The reference standard values of the standardized markers will be considered for the evaluations.

  3. Effects of MRgFUS on the joint organ: pain

    Time frame: Baseline (Day 1), 24 hours post MRgFUS, Month 1, 3, 6,12

    Enzyme linked immuno assays kits will be used to test pain markers in serum. The reference standard values of the standardized markers will be considered for the evaluations.

  4. Effects of MRgFUS on the joint organ: cartilage turnover

    Time frame: Baseline (Day 1), 24 hours post MRgFUS, Month 1, 3, 6,12

    Enzyme linked immuno assays kits will be used to test cartilage turnover markers in urine. The reference standard values of the standardized markers will be considered for the evaluations.

Sponsors and collaborators

Lead sponsor

Istituto Ortopedico Rizzoli

Other

Registry information

Official study title

Pain in Knee Osteoarthritis, a Placebo-controlled Randomized Clinical Trial for a New Potential Therapeutic Approach: Magnetic Resonance Guided Focused Ultrasound Surgery (MRgFUS)

Important dates

Study start
2018
Primary completion
2019
Study completion
2020
First posted
Mar 5, 2018
Registry last updated
May 11, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.